CAJ | 학술논문

目的：观察中药安脑片对急性移植物抗宿主病（aGVHD）小鼠的转化生长因子β1（TGF-β1）表达的影响，以探求其干预aGVHD 的机制。方法：SPF级Balb/c 雄性小鼠作为供鼠，以SPF级C57BL/6雌性小鼠为受鼠，建立 aGVHD 模型，随机分为安脑片组和空白组，每组20只。移植后第14天及第30天留取标本，运用ELISA 法检测小鼠血清TGF-β1、Western Blot 法检测脾脏TGF-β1蛋白的表达及荧光定量PCR 法检测脾组织中TGF-β1 mRNA 表达。结果：ELISA 法检测小鼠血清TGF-β1的结果显示，治疗前两组小鼠血清TGF-β1浓度的差异无统计学意义（P＝0．305），治疗后第14及30天，安脑片组小鼠血清TGF-β1的浓度分别为（148．31±7．95）及（183．48±5．91）ng/mL，而空白组为（118．97±2．58）ng/mL，两组相比差异有显著性意义（P＝0．000）。 Western Blot 法检测脾脏 TGF-β1蛋白表达的结果显示，治疗后第14天，安脑组小鼠TGF-β1蛋白的 IOD/IODβ-actin值为0．33±0．05，治疗后30 d，其值继续上升至0．56±0．04，比值均显著高于空白组（P＝0．000）。荧光定量PCR检测脾组织中TGF-β1 mRNA表达的结果显示，治疗后第14及30天，安脑片组小鼠TGF-β1 mRNA 表达水平分别为1．24±0．04及2．14±0．33，而空白组小鼠TGF-β1 mRNA 的表达较治疗前无明显变化。结论：安脑片可通过提高血清 TGF-β1的浓度、提高脾脏 TGF-β1蛋白、mRNA 表达，有效减轻异体移植小鼠aGVHD 的症状和程度。
목적：관찰중약안뇌편대급성이식물항숙주병（aGVHD）소서적전화생장인자β1（TGF-β1）표체적영향，이탐구기간예aGVHD 적궤제。방법：SPF급Balb/c 웅성소서작위공서，이SPF급C57BL/6자성소서위수서，건립 aGVHD 모형，수궤분위안뇌편조화공백조，매조20지。이식후제14천급제30천류취표본，운용ELISA 법검측소서혈청TGF-β1、Western Blot 법검측비장TGF-β1단백적표체급형광정량PCR 법검측비조직중TGF-β1 mRNA 표체。결과：ELISA 법검측소서혈청TGF-β1적결과현시，치료전량조소서혈청TGF-β1농도적차이무통계학의의（P＝0．305），치료후제14급30천，안뇌편조소서혈청TGF-β1적농도분별위（148．31±7．95）급（183．48±5．91）ng/mL，이공백조위（118．97±2．58）ng/mL，량조상비차이유현저성의의（P＝0．000）。 Western Blot 법검측비장 TGF-β1단백표체적결과현시，치료후제14천，안뇌조소서TGF-β1단백적 IOD/IODβ-actin치위0．33±0．05，치료후30 d，기치계속상승지0．56±0．04，비치균현저고우공백조（P＝0．000）。형광정량PCR검측비조직중TGF-β1 mRNA표체적결과현시，치료후제14급30천，안뇌편조소서TGF-β1 mRNA 표체수평분별위1．24±0．04급2．14±0．33，이공백조소서TGF-β1 mRNA 적표체교치료전무명현변화。결론：안뇌편가통과제고혈청 TGF-β1적농도、제고비장 TGF-β1단백、mRNA 표체，유효감경이체이식소서aGVHD 적증상화정도。
Objective To study the influence of Annao tablet on the expression of transforming growth factor beta 1 (TGF-β1) in acute graft-versus-host disease (aGVHD) murine and to explore the interventional mechanism of TGF-β1 on aGVHD. Methods Hematopoietic stem cells of male Balb/c mice were transplanted to female C57BL/6 mice for the development of aGVHD murine model. Recipient mice were divided into Annao group and blank group randomly and respectively administrated with Annao soup (a kind of Chinese herb) and 0.9% sodium chloride intragastrically. Clinical symptom, survival time and body weight were recorded at 14th and 30th day and some sections of liver, small bowel and skin were taken for histological changes. Serum level of TGF-β1 were measured by enzyme-labeled immunosorbent assay (ELISA), splenocyte protein of TGF-β1 by Western Blot and TGF-β1 mRNA by fluorescent quantitation polymerase chain reaction (PCR). Results Serum level of TGF-β1 in both groups had no statistical difference (P = 0.305), but it rose to (148.31 ± 7.95) ng/mL at 14th day and (183.48 ± 5.91) ng/mL at 30th day in Annao group, which had significant difference when compared with that in blank group (P = 0.000). IOD/IODβ-actin value of TGF-β1 protein in Annao group was 0.33 ± 0.05 at 14th day and 0.56 ± 0.04 at 30th day, which was higher than that in blank group (P = 0.000) and the expression of TGF-β1 mRNA of splenocyte in Annao group was 1.24 ± 0.04 at 14th day and 2.14 ± 0.33 at 30th day which was much higher than that in blank group (P = 0.000). Conclusion Annao tablet helps to relieve symptoms of acute GVHD by raising serum level of TGF-β1 and intensifying expression of protein of TGF-β1 and its mRNA.